NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage pharmaceutical company that reached the public markets through a business combination with Big Rock Partners Acquisition Corp., a blank-check vehicle that completed its initial public offering in 2018 with a focus on healthcare and life sciences targets. Big Rock Partners LLC served as sponsor. The Form 10-K filed in March 2019 covers fiscal year 2018 activity, representing an annual disclosure during the SPAC's search period. The combined entity, operating under the NRXP ticker, has concentrated on developing treatments for central nervous system disorders and critical-care conditions. Sign up on SpacDesk for comprehensive filing history, deal timelines, and post-merger analytics on NRXP.